US court rejects Glenmark's patent plea for Finacea

Drug firm Glenmark's generic skin care drug that was under patent litigation infinges patent of Bayer, a US court has ruled.

New York: Drug firm Glenmark's generic skin care drug that was under patent litigation infinges patent of Bayer, a US court has ruled.

The US District Court of Delaware at Wilmington, has said that claims of Bayer Healthcare Pharmaceuticals Inc, Intendis and Intraserv's litigation for Bayer's Finacea, a gel for treating the common skin condition rosacea against Glenmark is valid.

The court came to the conclusion that Glenmark had infringed the "070 patent" of the plaintiffs and "that asserted claims of 070 patents are valid "and ordered the judgement in favour of Bayer and other plaintiffs.

The companies had filed a case against Glenmark in 2013 after it had filled an Abbreviated New Drug Application (ANDA) seeking to market a generic azelaic acid hydrogel in 2012.

Bayer Healthcare Pharmaceuticals Inc is the holder of approved New Drug Application for Finacea gel.

Glenmark currently employs over 10,400 people in over 80 countries. It has 14 manufacturing facilities in four countries and has 6 R&D centres.

By continuing to use the site, you agree to the use of cookies. You can find out more by clicking this link

Close